Stockscreener 앱 받기
183.41
0.60%
1.10
시간 외 거래:
187.25
3.84
+2.09%
전일 마감가:
$182.31
열려 있는:
$182.18
하루 거래량:
758.50K
Relative Volume:
0.48
시가총액:
$26.92B
수익:
$9.53B
순이익/손실:
$1.29B
주가수익비율:
20.83
EPS:
8.8057
순현금흐름:
$1.97B
1주 성능:
-0.81%
1개월 성능:
-4.51%
6개월 성능:
+28.71%
1년 성능:
+29.68%
1일 변동 폭
$181.68
$185.44
1주일 범위
$180.48
$188.00
52주 변동 폭
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
명칭
Biogen Inc
전화
(781) 464-2000
주소
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
183.41 | 26.76B | 9.53B | 1.29B | 1.97B | 8.8057 |
|
LLY
Lilly Eli Co
|
917.50 | 819.81B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
237.60 | 571.52B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
206.23 | 368.38B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
188.93 | 292.21B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
148.19 | 285.86B | 54.72B | 14.02B | 15.32B | 7.1855 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-09 | 재확인 | H.C. Wainwright | Buy |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-10 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2025-11-06 | 업그레이드 | Stifel | Hold → Buy |
| 2025-09-25 | 개시 | Jefferies | Buy |
| 2025-07-21 | 재개 | Truist | Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-04-04 | 다운그레이드 | Argus | Buy → Hold |
| 2025-02-11 | 개시 | Bernstein | Mkt Perform |
| 2025-01-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-11-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-31 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-02-14 | 재확인 | Needham | Buy |
| 2024-02-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-12-20 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-12-07 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-24 | 재확인 | UBS | Buy |
| 2023-05-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-04-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-10-13 | 업그레이드 | Stifel | Hold → Buy |
| 2022-10-07 | 업그레이드 | Argus | Hold → Buy |
| 2022-09-28 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-28 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 재확인 | Barclays | Equal Weight |
| 2022-02-04 | 재확인 | BofA Securities | Neutral |
| 2022-02-04 | 재확인 | Cowen | Outperform |
| 2022-02-04 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-04 | 재확인 | Needham | Buy |
| 2022-02-04 | 재확인 | Oppenheimer | Outperform |
| 2022-02-04 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 재확인 | Robert W. Baird | Neutral |
| 2022-02-04 | 재확인 | Wedbush | Neutral |
| 2022-02-04 | 재확인 | Wells Fargo | Equal Weight |
| 2022-02-04 | 재확인 | Wolfe Research | Peer Perform |
| 2022-01-13 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-01-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-06-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 재확인 | Truist | Buy |
| 2021-06-11 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-08 | 업그레이드 | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 재확인 | Barclays | Equal Weight |
| 2021-06-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-08 | 재확인 | Jefferies | Buy |
| 2021-06-08 | 재확인 | Morgan Stanley | Overweight |
| 2021-06-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 재확인 | Stifel | Buy |
| 2021-06-08 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-07 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-06-07 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2021-01-29 | 업그레이드 | Stifel | Hold → Buy |
| 2020-11-10 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-11-09 | 다운그레이드 | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-11-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-11-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-04 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2020-11-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-11-04 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-07-27 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-04-23 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-27 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
모두보기
Biogen Inc 주식(BIIB)의 최신 뉴스
Biogen to present litifilimab data for cutaneous lupus at AAD - Investing.com
Securities Litigation on Behalf of Purchasers of Biogen, Inc. Securities (BIIB) Certified as Class Action - GlobeNewswire Inc.
A lupus skin disease with no targeted treatment gets new Biogen data - Stock Titan
The Escalator: Biogen, Flagship Pioneering, Grail and more - Medical Marketing and Media
Insight Wealth Strategies LLC Buys Shares of 28,960 Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Shares Sold by Hudson Bay Capital Management LP - MarketBeat
Biogen Conference: Tau ASO CELIA Updates, Pre-Symptomatic Leqembi, SMA Phase 3 Plans - Yahoo Finance
Why Biogen Inc. (BIIB) is a top value stock for the long term - MSN
Here's why Biogen Inc. (BIIB) is a strong momentum stock - MSN
Biogen at Stifel Forum: Strategic Insights on Alzheimer’s and Neuromuscular Advances - Investing.com
BIIB: Advances in Alzheimer's, SMA, and immunology pipelines highlight innovation and pivotal trials - TradingView
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
HSBC Maintains Reduce Rating for BIIB, Raises Price Target | BII - GuruFocus
Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, HSBC Analyst Says - MarketBeat
Biogen Legal Chief Exit Puts Focus On Valuation Gap And Returns - simplywall.st
Dow Update: Is Biogen Inc showing insider buying2026 Breakouts & Fast Momentum Entry Tips - baoquankhu1.vn
Gotham Asset Management Boosts Biogen Stake by 65% - National Today
Gotham Asset Management LLC Has $37.89 Million Position in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Stock Holdings Boosted by Brevan Howard Capital Management LP - MarketBeat
Behavioral Patterns of BIIB and Institutional Flows - Stock Traders Daily
Banco Bilbao Vizcaya Argentaria S.A. Increases Stake in Biogen Inc. $BIIB - MarketBeat
Capula Management Ltd Takes $1.43 Million Position in Biogen Inc. $BIIB - MarketBeat
Cinctive Capital Management LP Raises Stake in Biogen Inc. $BIIB - MarketBeat
Suvretta Capital Management LLC Has $23.56 Million Stake in Biogen Inc. $BIIB - MarketBeat
iSAM Funds UK Ltd Has $2.41 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Does New Once-Yearly SMA Data And Phase 3 Plan Change The Bull Case For Biogen (BIIB)? - simplywall.st
Biogen CLO Retiring After 20 Years With Biopharma Biz - Law360
Biogen's Legal Chief for 2 Decades Exiting in May - Law.com
Legal & General Group Plc Buys 146,583 Shares of Biogen Inc. $BIIB - MarketBeat
BIIB Stock Price, Quote & Chart | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Biogen Details West Coast Hub, Felzartamab Phase 3 Plans and AMR Readout Timeline at Conference - Yahoo Finance
Biogen Rare Disease Data And Valuation Discount Draw Investor Attention - Yahoo Finance
Assessing Biogen (BIIB) Valuation After Recent Shareholder Return Momentum - simplywall.st
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders - BioSpace
Biogen’s Spinraza successor benefits SMA patients unresponsive to gene therapy - Yahoo
Swiss National Bank Cuts Stake in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. Announces Departure of Chief Legal Officer Susan H. Alexander Effective May 2026 - Minichart
Biogen Inc. $BIIB Shares Sold by Dimensional Fund Advisors LP - MarketBeat
Biogen presents Phase 1b data on salanersen for SMA treatment - Investing.com South Africa
Biogen Announces Upcoming Departure of Chief Legal Officer - TipRanks
Biogen chief legal officer Susan H. Alexander to depart at end of May - Investing.com
Oppenheimer reiterates Biogen stock rating on SMA drug data By Investing.com - Investing.com Nigeria
Susan H. Alexander to Depart as Biogen Chief Legal Officer - TradingView
Oppenheimer reiterates Biogen stock rating on SMA drug data - Investing.com
Biogen (NASDAQ: BIIB) Chief Legal Officer Susan Alexander to depart - Stock Titan
Biogen Inc. Announces Departure of Chief Legal Officer Susan H. Alexander, Effective End of May 2026 - marketscreener.com
Biogen Unveils Phase III Salanersen Program To Bring Longer-Acting SMA Option - Citeline News & Insights
Biogen builds case for Spinraza successor with fresh data - BioPharma Dive
To promote Zurzuvae, Biogen and Supernus are Turning Tides against postpartum depression - Medical Marketing and Media
Biogen Stock: Is BIIB Outperforming the Healthcare Sector? - Barchart
Biogen Inc (BIIB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.33%
0.99%
자본화:
|
볼륨(24시간):